Company intelligence / Profile preview

Regencor

San Mateo (HQ), California, United Statesregencor.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Regencor’s lead program REG101 has demonstrated regenerative properties in several large animal studies by stimulating the proliferation of cardiomyocytes after MI. The company reports compelling preclinical data showing reversal of scar tissue formation and restoration of contractile function. No human clinical results yet; IND-enabling studies are ongoing with first-in-human trials planned for late 2025

Therapeutic areas: Cardiovascular
Modalities: Recombinant protein therapeutics (specifically REG101, a proprietary biologic/protein)
Industry: Biotech

Drug pipeline

4 assets

hgFSTL-1

Preclinical

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Regencor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regencor.

Explore the full profile